Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator. It is a major ...

The Astellas UK affiliate was already suspended for a year in June 2016 after it took doctors to a medical conference in Milan, Italy which included a presentation about benefits of its Xtandi ...

3382.T Seven & i Holdings Co., Ltd.

(RTTNews) - Astellas Pharma Inc. (ALPMY) Thursday said it has signed an agreement with Sangamo Therapeutics, Inc. (SGMO) to leverage Sangamo's proprietary neurotropic adeno-associated virus (AAV ...

Astellas Pharma (TYO: 4503) has struck a licensing agreement with Sangamo Therapeutics (Nasdaq: SGMO) to make use of its neurotropic adeno-associated virus capsid, STAC-BBB. This innovative technology ...

Please view our affiliate disclosure. Creating a strong brand identity is one of the most important aspects of a business. A well-designed logo is often the first impression a company makes on ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Astellas Pharma (ALPMY) and Sangamo (SGMO) announced they have entered into a license agreement allowing Astellas to leverage Sangamo’s neurotropic adeno-associated virus capsid, STAC-BBB, which ...

Astellas Pharma US, Inc. announced this week it is voluntarily pulling one lot of PROGRAF 0.5mg and one lot of ASTAGRAF XL 0.5mg from consumer shelves because empty capsules that may be contained ...

Agreement grants Astellas rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - Sangamo to receive a $20 million upfront license fee ...

Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s product portfolio comprises marketed products for the treatment of a ...